Bolt Biotherapeutics Announces It Will Host Key Opinion Leader Conference Call And Webcast To Discuss BDC-3042 Phase 1 Results Monday, May 12, 2025 At 2:30 P.M. PT / 5:30 P.M. ET.

Author: Benzinga Newsdesk | May 08, 2025 08:08am

• Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET

- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET.

Dr. Dumbrava will discuss the results from the Phase 1 dose-escalation clinical study of BDC-3042 that were presented at the American Associates for Cancer Research (AACR) Annual Meeting that took place in April 2025. In addition, Bolt's management team will discuss BDC-3042 partnering plans, present an update on BDC-4182 clinical development, and provide an update on first quarter 2025 financial results. A live Q&A will follow the prepared remarks.

Bolt Biotherapeutics will host a conference call and webcast featuring Dr. Dumbrava on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The conference call and webcast can be accessed via this link https://edge.media-server.com/mmc/p/q6d3u5uv/. A replay of the event will be available for a limited time under Events and Presentations in the Investors section of the Company's website at investors.boltbio.com/events-and-presentations.

Posted In: BOLT